Postoperative Pain - Pipeline Insight, 2025
Description
DelveInsight’s, “Postoperative Pain - Pipeline Insight, 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Postoperative Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Postoperative Pain: Overview
Postoperative or Postsurgical pain is defined as pain lasting more than 3 to 6 months after surgery. The pain differs in quality and location from pain experienced prior to surgery, and is usually associated with iatrogenic neuropathic pain caused by surgical injury to a major peripheral nerve. Although all types of surgery can lead to persistent postoperative pain (PPP), some surgeries are at higher risk of causing nerve damage, such as inguinal hernia repair, breast and thoracic surgery, leg amputation, and coronary artery bypass surgery. Consequently, surgical techniques that avoid nerve damage should be applied whenever possible. Postoperative pain can be divided into acute pain and chronic pain. Acute pain is experienced immediately after surgery (up to 7 days) and pain which lasts more than 3 months after the injury is considered to be chronic pain. Acute and chronic pain can arise from cutaneous, deep somatic or visceral structures.
The pathophysiology of the disease involves surgery, by nature, involves the cutting of tissues and nerves, which induces the injury response (inflammation, hyperalgesia) and alterations of peripheral and central nervous system (CNS) pain processing (central sensitization), which can lead to chronic pain. After peripheral nerve injury, increased sodium-channel (Na) expression on sensitized primary afferent nerves leads to spontaneous activity with increased glutamate release from the nerve endings. This excess of glutamate acts on glutamate receptors (N-methyl-D-aspartate [NMDA], α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid [AMPA], kainate, and metabotropic glutamate receptors [mGluRs]), thereby triggering intracellular changes. These changes contribute to sustained central sensitization, with increased spontaneous impulse discharges, reduced thresholds, increased response to peripheral stimuli, and expanded receptive fields of central neurons. Central sensitization is an amplification of pain signaling in the spinal cord from repeated stimulation from the periphery. Surgery increases synaptic activity in dorsal horn neurons. Humoral signals released from inflamed tissue act on the CNS and intracellular kinases. Within hours, altered gene transcription in the dorsal root ganglion (DRG) of sensory neurons and the spinal cord augment release of excitatory transmitters and reduce inhibitory transmitters. This results in neuronal excitability lasting days. When the noxious stimuli continue, then neuroplastic transformations occur and a positive feedback loop forms. Over time, neurons change structure, function, or chemical profile leading to pain as a disease
The effective treatment plan of postoperative pain includes a number of factors, including good nursing, non-pharmacological techniques, such as distraction, and balanced (multimodal) analgesia to provide adequate pain relief with optimal drug combinations used at the lowest effective doses. Postoperative pain management should be step-wise and balanced. Balanced (multimodal) analgesia: Balanced (multimodal) analgesia uses two or more analgesic agents that act by different mechanisms to achieve a superior analgesic effect without increasing adverse events compared with increased doses of single agents. Opioid Analgesia it is the most commonly used intravenous opioids for postoperative pain are morphine, hydromorphone (dilaudid), and fentanyl. Morphine is the standard choice for opiates and is widely used. It has a rapid onset of action with peak effect occurring in 1 to 2 hours.
""Postoperative Pain - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postoperative Pain pipeline landscape is provided which includes the disease overview and Postoperative Pain treatment guidelines. The assessment part of the report embraces, in depth Postoperative Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postoperative Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Postoperative Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Postoperative Pain Emerging Drugs
Further product details are provided in the report……..
Postoperative Pain: Therapeutic Assessment
This segment of the report provides insights about the different Postoperative Pain drugs segregated based on following parameters that define the scope of the report, such as:
Postoperative Pain: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postoperative Pain therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postoperative Pain drugs.
Postoperative Pain Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Postoperative Pain: Overview
Postoperative or Postsurgical pain is defined as pain lasting more than 3 to 6 months after surgery. The pain differs in quality and location from pain experienced prior to surgery, and is usually associated with iatrogenic neuropathic pain caused by surgical injury to a major peripheral nerve. Although all types of surgery can lead to persistent postoperative pain (PPP), some surgeries are at higher risk of causing nerve damage, such as inguinal hernia repair, breast and thoracic surgery, leg amputation, and coronary artery bypass surgery. Consequently, surgical techniques that avoid nerve damage should be applied whenever possible. Postoperative pain can be divided into acute pain and chronic pain. Acute pain is experienced immediately after surgery (up to 7 days) and pain which lasts more than 3 months after the injury is considered to be chronic pain. Acute and chronic pain can arise from cutaneous, deep somatic or visceral structures.
The pathophysiology of the disease involves surgery, by nature, involves the cutting of tissues and nerves, which induces the injury response (inflammation, hyperalgesia) and alterations of peripheral and central nervous system (CNS) pain processing (central sensitization), which can lead to chronic pain. After peripheral nerve injury, increased sodium-channel (Na) expression on sensitized primary afferent nerves leads to spontaneous activity with increased glutamate release from the nerve endings. This excess of glutamate acts on glutamate receptors (N-methyl-D-aspartate [NMDA], α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid [AMPA], kainate, and metabotropic glutamate receptors [mGluRs]), thereby triggering intracellular changes. These changes contribute to sustained central sensitization, with increased spontaneous impulse discharges, reduced thresholds, increased response to peripheral stimuli, and expanded receptive fields of central neurons. Central sensitization is an amplification of pain signaling in the spinal cord from repeated stimulation from the periphery. Surgery increases synaptic activity in dorsal horn neurons. Humoral signals released from inflamed tissue act on the CNS and intracellular kinases. Within hours, altered gene transcription in the dorsal root ganglion (DRG) of sensory neurons and the spinal cord augment release of excitatory transmitters and reduce inhibitory transmitters. This results in neuronal excitability lasting days. When the noxious stimuli continue, then neuroplastic transformations occur and a positive feedback loop forms. Over time, neurons change structure, function, or chemical profile leading to pain as a disease
The effective treatment plan of postoperative pain includes a number of factors, including good nursing, non-pharmacological techniques, such as distraction, and balanced (multimodal) analgesia to provide adequate pain relief with optimal drug combinations used at the lowest effective doses. Postoperative pain management should be step-wise and balanced. Balanced (multimodal) analgesia: Balanced (multimodal) analgesia uses two or more analgesic agents that act by different mechanisms to achieve a superior analgesic effect without increasing adverse events compared with increased doses of single agents. Opioid Analgesia it is the most commonly used intravenous opioids for postoperative pain are morphine, hydromorphone (dilaudid), and fentanyl. Morphine is the standard choice for opiates and is widely used. It has a rapid onset of action with peak effect occurring in 1 to 2 hours.
""Postoperative Pain - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postoperative Pain pipeline landscape is provided which includes the disease overview and Postoperative Pain treatment guidelines. The assessment part of the report embraces, in depth Postoperative Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postoperative Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Postoperative Pain R&D. The therapies under development are focused on novel approaches to treat/improve Postoperative Pain.
This segment of the Postoperative Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Postoperative Pain Emerging Drugs
- VVZ-149: Vivozon Pharmaceutical Inc.
- LC-400: LipoCure
- INSB-200: InSitu Biologics
Further product details are provided in the report……..
Postoperative Pain: Therapeutic Assessment
This segment of the report provides insights about the different Postoperative Pain drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Postoperative Pain
- There are approx. 45+ key companies which are developing the therapies for Postoperative Pain. The companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. phase III include, Vivozon Pharmaceutical Inc.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Postoperative Pain: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postoperative Pain therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postoperative Pain drugs.
Postoperative Pain Report Insights
- Postoperative Pain Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Postoperative Pain drugs?
- How many Postoperative Pain drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postoperative Pain?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Postoperative Pain therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Postoperative Pain and their status?
- What are the key designations that have been granted to the emerging drugs?
- Vivozon Pharmaceutical Inc.
- Concentric Analgesics
- LipoCure
- InSitu Biologics
- Bexson Biomedical
- Allay Therapeutics
- Jiangsu HengRui Medicine Co., Ltd.
- Nevakar, Inc
- Oculis Pharma
- Cytogel Pharma
- Camurus
- Taiwan Liposome Company
- Teikoku Pharma USA
- Salvat
- Avenue Therapeutics
- Cali Pharmaceuticals
- Bayer
- VVZ-149
- CA-008
- LC-400
- INSB-200
- BB-106
- ATX-201
- HR021618
- NVK-009
- OCS-01
- CYT-1010
- CAM2048
- TLC-590
- TPU-006
- SVT-15473
- AVE-901
- CPL-01
- BAY2880376
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Postoperative Pain : Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Postoperative Pain – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- VVZ-149: Vivozon Pharmaceutical Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Product Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- LC-400: LipoCure
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- INSB-200: InSitu Biologics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Postoperative Pain Key Companies
- Postoperative Pain Key Products
- Postoperative Pain - Unmet Needs
- Postoperative Pain - Market Drivers and Barriers
- Postoperative Pain - Future Perspectives and Conclusion
- Postoperative Pain Analyst Views
- Postoperative Pain Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
